Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo tested in fight against advanced cancers

NCT ID NCT05935098

Summary

This early-stage study tested a new drug called BGB-A3055, both alone and combined with another cancer drug (tislelizumab), in people with advanced solid tumors that had spread. The main goals were to find a safe dose and see if the treatment showed early signs of fighting the cancer. The study was terminated early and involved 99 participants who had already tried standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Advent Health Cancer Institute

    Orlando, Florida, 32804-4603, United States

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, 05505, South Korea

  • Centre de Lutte Contre Le Cancer Institut Bergonie

    Bordeaux, 33000, France

  • Changzhi Peoples Hospital

    Changzhi, Shanxi, 046099, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109-4433, United States

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Ico Site Rene Gauducheau

    SaintHerblain, 44805, France

  • Icon Cancer Centre South Brisbane

    South Brisbane, Queensland, 4101, Australia

  • Institut Curie

    Paris, 75005, France

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • John Theurer Cancer Center Hackensack University Medical Center

    Hackensack, New Jersey, 07601-2191, United States

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, 110042, China

  • Linear Clinical Research

    Nedlands, Western Australia, 6009, Australia

  • Next Dallas

    Irving, Texas, 75039-2743, United States

  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicinejiading Branch

    Shanghai, Shanghai Municipality, 201801, China

  • Samsung Medical Center

    GangnamGu, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Bundang Hospital

    BundangGu SeongnamSi, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242-1009, United States

Conditions

Explore the condition pages connected to this study.